Acarix AB (publ) (ACARIX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

And thank you for joining the ACARIS Q3 2025 earnings call. Before we get into the Q3 outcomes, which we're really excited to present, I wanted to address all the challenges that are being faced across the globe in response to geopolitical challenges, geopolitical rhetoric. with incontinent structures, including the U.S., which is currently shut down. A lot of challenges globally, and we are evaluating them and address them very quickly and nimbly, including some questions that came in regarding tariffs and what that exposure looks like for our carrots. We are addressing it, and given our great value proposition, including our gross margin, we are not overly concerned with the tariff of 10% currently, but we are reflecting and leveraging resources to evaluate onshoring opportunity within the U.S. because we will effectively deliver on a redundancy capacity in the near future as well. So rest assured that we are watching it diligently, watching it on a day-to-day basis, even an hourly basis, to understand everything that's procuring, that we're making sure we're driving shareholder value and making sure our organization is ready for any changes that could procure. With that, we'll jump into the entirety of Acarix and our Q3 2025 earnings. But initially, we'll discuss GASCOR and Acarix as a company for a lot of the new investors that have joined us. So GASCOR is a device that leverages high-fidelity acoustics and computational learning to re-stratify patients at that point of care, meaning anywhere in the world, and it does so within four to six minutes. One of the key factors here is that Acaryx has had over 15 years of R&D, over 45 patents, 6,000 patients in clinical trials, and over 47,000 uses worldwide. Really established organization with a ton of potential. One ...